1. Introduction {#sec1-cancers-10-00028}
===============

Oncolytic virotherapy is a novel therapeutic modality that directly induces the lysis of infected tumor cells, and subsequently enhances host immune responses \[[@B1-cancers-10-00028],[@B2-cancers-10-00028],[@B3-cancers-10-00028],[@B4-cancers-10-00028]\]. Recent clinical studies demonstrated that oncolytic viral therapy increases cytokines, activates immune responses, and effectively destroys primary and metastatic lesions, even if the virus does not reach distant lesions. Therefore, oncolytic viruses are also considered to be immunotherapeutic agents \[[@B5-cancers-10-00028]\]. Herpes simplex virus type 1 (HSV-1) is one of the most widely studied viruses for the treatment of patients with solid tumors. Oncolytic HSV-1 lacks the neurovirulence gene γ34.5, which is responsible for encephalitis, as a requisite gene modification for safety \[[@B6-cancers-10-00028],[@B7-cancers-10-00028]\].

In microbial infection, pathogen-associated molecular patterns (PAMPs) that exist in diverse organisms, but not in the host, provide exogenous signal regarding the presence of pathogens in the immune system, thereby promoting immunity \[[@B8-cancers-10-00028],[@B9-cancers-10-00028]\]. In contrast, cells release damage-associated molecular patterns (DAMPs) as endogenous signals that alert the immune system to respond to unexpected cell death, microbial invasion, and stress \[[@B3-cancers-10-00028],[@B10-cancers-10-00028]\]. DAMPs may be proteins, nucleic acids, or metabolic products. Protein DAMPs include intracellular proteins such as high mobility group box 1 (HMGB1), heat shock protein (HSP), hyaluronic acid, calreticulin (CRT), and S100 protein \[[@B3-cancers-10-00028],[@B5-cancers-10-00028]\]. When solid tumors are infected with oncolytic viruses, the virus mostly induces immunogenic cell death (ICD), resulting in the cell surface exposure of CRT and HSP and release of ATP, HMGB1, uric acid, other DAMPs, PAMPs, and tumor-associated antigens (TAAs) \[[@B3-cancers-10-00028],[@B11-cancers-10-00028],[@B12-cancers-10-00028],[@B13-cancers-10-00028]\].

Previously, we reported that an injection of oncolytic HSV-1 strain RH2 into squamous cell carcinoma cell (SCC) SCCVII tumors in inbred mice enhanced systemic anti-tumor immunity \[[@B14-cancers-10-00028]\], and that cell death caused by RH2 was immunogenic cell death (ICD) with the release of DAMPs such as ATP and HMGB1 \[[@B13-cancers-10-00028]\]. We also indicated that intratumoral injection of the supernatants of RH2-infected cells suppressed tumor growth, even if infectivity was lost by ultraviolet irradiation, suggesting their ability to enhance antitumor immunity \[[@B13-cancers-10-00028]\].

Secreted proteins comprise an important group of molecules encoded by about 10% of the human genome, and are able to reflect a broad variety of different conditions of the cell \[[@B15-cancers-10-00028]\]. A proteomic analysis of human macrophages infected with HSV-1 demonstrated the release of proteins functionally related to metabolic processes, transport, stress responses, cell death, proteolysis, the extracellular matrix (ECM), and cell adhesion \[[@B16-cancers-10-00028]\]. However, the characteristics of the secreted proteins, secretomes, of oncolytic HSV-1-infected tumor cells have not yet been studied. In the present study, we performed proteomic analysis of ecretomes of RH2-infected and mock-infected SCC cells, and compared the protein profiles.

2. Results {#sec2-cancers-10-00028}
==========

2.1. Classification of Released Proteins of Med24 and MedC {#sec2dot1-cancers-10-00028}
----------------------------------------------------------

The supernatants of RH2-infected SCCVII cells and mock-infected cells were harvested and concentrated to produce samples named Med24 and MedC. Med24 and MedC were sequentially analyzed, and isobaric tag for relative and absolute quantitation (iTRAQ) quantitation was performed for each protein. A total of 1567 proteins were detected in Med24 and 1344 in MedC, with 223 extracellular proteins being increased by RH2 infection. Based on the results of iTRAQ quantitation, MedC proteins spontaneously secreted from SCCVII cells were classified into three categories, i.e., high, medium, and low abundance groups. The numbers of proteins in the high, medium, and low abundance groups were 190, 262, and 892, respectively.

In order to examine the effects of RH2 infection on protein secretion, iTRAQ quantitation data for each protein was compared between Med24 and MedC. Protein release was found to be up- or down-regulated by RH2 infection. In the high abundance group, 29 proteins were up-regulated by more than 1.4 fold by RH2 infection ([Table 1](#cancers-10-00028-t001){ref-type="table"}). However, a significant increase was observed in 16 proteins. They included filamin alpha, tubulin beta-4B, clathrin heavy chain, t-complex protein 1 (TCP-1) subunit beta, theta, alpha, gamma and delta, bifunctional purine biosynthesis protein (PURH), filamin-C, bifunctional glutamate/proline--tRNA ligase, plastin-3, fascin, coatomer subunit alpha, beta enolase, and tubulin beta-6 chain.

In the high abundance group of MedC, 50 proteins were down-regulated by more than 50% by RH2 infection ([Table 2](#cancers-10-00028-t002){ref-type="table"}). They included ECM components such as fibronectin, thrombospodin-1, basement membrane-specific heparin sulfate proteoglycan core protein, fibrillin-1, chondroitin sulfate proteoglycan 4, SPARC, procollagen C, collagen alpha, and extracellular matrix protein 1. Other proteins, cathepsin B, cathepsin D, matrixmetalloproteinase-9, and 72 kDa type IV collagenase, were involved in the remodeling of ECM. Among all proteins listed, a significant difference was observed between the Med24 and MedC groups.

2.2. Alteration of DAMPs and DAMPs-Related Proteins in the Secretomes {#sec2dot2-cancers-10-00028}
---------------------------------------------------------------------

In DAMPs, the numbers of high, medium, and low abundance proteins were 11, 6, and 3, respectively ([Table 3](#cancers-10-00028-t003){ref-type="table"}). In the high abundance group, HSPs, actin cytoplasmic 1, annexin A1, annexin A2, galectin-1, peroxiredoxin-2, and histone H2B type 1 were observed. Only the levels of HSP90-beta, actin cytoplasmic 1, and galectin-3 were significantly higher in Med24 than in MedC. ATP-citrate, which is responsible for the production of ATP, a known DAMP, was also detected as a significantly elevated protein ([Table 3](#cancers-10-00028-t003){ref-type="table"}).

2.3. Viral Proteins in the Secretomes {#sec2dot3-cancers-10-00028}
-------------------------------------

Twenty-nine viral proteins that were detected in Med24 were not present in MedC ([Table 4](#cancers-10-00028-t004){ref-type="table"}). When viral proteins were categorized into three groups, the numbers of proteins in the high, medium, and low abundance groups were 8, 9, and 12, respectively. Major capsid protein unique sequence of the L component (UL) 19, tegument protein UL37, capsid protein virion polypeptide (VP) 23, glycoprotein D, and glycoprotein E were identified as viral structural proteins. In addition, ribonucleoside-diphosphate reductase, single-strand DNA-binding protein, DNA polymerase processivity subunit, transcriptional regulator infected cell protein (ICP) 4, exonuclease (UL12), multifunctional expression regulator (ICP27), and deoxyuridine triphosphatase were identified as high abundance proteins in Med24 ([Table 4](#cancers-10-00028-t004){ref-type="table"}).

3. Discussion {#sec3-cancers-10-00028}
=============

Proteomic analysis has been applied to HSV-1 virion-incorporated host proteins, cellular proteins interacting with viral proteins such as ICP27, ICP8, and VP16, and protein profiles in HSV-1-infected cells \[[@B17-cancers-10-00028],[@B18-cancers-10-00028],[@B19-cancers-10-00028]\]. Miettinen et al. \[[@B16-cancers-10-00028]\] characterized the secretome of HSV-1-infected human primary macrophage using high-throughput quantitative proteomics, and identified 516 distinct proteins from macrophages secretome upon HSV-1 infection, and the secretion of 411 proteins was \>2-fold increased upon interferon β (IFN-β) priming and/or HSV-1 infection. Based on our previous findings that the supernatants of RH2-infected cells suppressed the tumor growth in mice \[[@B13-cancers-10-00028]\], we hypothesized that the supernatants contained immunostimulatory proteins, and performed proteomic analysis of the secretomes. Since the amounts of proteins detectable in the secretomes were important, we classified MedC proteins into three categories based on the results of iTRAQ quantitation, and then determined whether they were up-regulated or down-regulated by RH2 infection. When the high abundance proteins that increased by more than 1.4 fold following RH2 infection were selected, 29 proteins fulfilled this criterion. However, a significant increase was only observed in 16 proteins, including filamin alpha, tubulin beta-4B, clathrin heavy chain, and TCP-1s ([Table 1](#cancers-10-00028-t001){ref-type="table"}).

Actin-binding proteins, filamin and pastin-3, and the actin-bundling protein, fascin, were identified as up-regulated high abundance proteins. An increase in tubulin, which is involved in the polymerization of microtubules, was demonstrated. Autoantibodies against filamin C were elevated in the patients with low-grade glioma and those against tubulin increased in the patients with nasopharyngeal carcinoma and neuroblastoma \[[@B20-cancers-10-00028],[@B21-cancers-10-00028],[@B22-cancers-10-00028]\]. Clathrin heavy chain is one of the most important proteins known to be involved in the secretion and transport of vesicles \[[@B23-cancers-10-00028]\]. Seliger et al. \[[@B24-cancers-10-00028]\] examined potential candidate biomarkers and novel targets for T-cell-based immunotherapies of renal carcinoma, and identified human leukocyte antigen class I ligands, including clathrin heavy chain. Filamin, tubulin, and clathrin may be potential immunogenic antigens in specific cancers.

We also identified TCP-1 family members as the major up-regulated proteins in Med24 secretomes. Chaperonin-containing TCP-1 (CCT), known as the TCP-1 ring complex (TRiC), forms an oligomer that consists of distinct subunits (alpha, beta, gamma, delta, epsilon, zeta, eta, and theta) occupying a fixed position within the two back-to-back chaperonin rings \[[@B25-cancers-10-00028]\]. CCT was originally identified as a molecular chaperone that is required for the folding of the highly abundant cytoskeletal proteins, actin and tubulin \[[@B26-cancers-10-00028]\]. The genes for CCT alpha and CCT beta were amplified in breast cancer and necessary for cancer growth and proliferation \[[@B27-cancers-10-00028]\]. CCT beta and CCT epsilon were overexpressed in both hepatocellular and colorectal cancers \[[@B28-cancers-10-00028],[@B29-cancers-10-00028]\]. Gao et al. \[[@B30-cancers-10-00028]\] reported that CCT5 (CCT epsilon) induced an autoantibody response in non-small cell lung cancer sera, and showed higher expression in cancer tissues. In the case of melanoma immunotherapy, mutated TCP 1-zeta-6A (CCT6A) antigen had previously been identified and proved to be immunogenic in a melanoma patient, so mutated CCT6A peptide was used as a model for patient-specific neoantigen \[[@B31-cancers-10-00028]\]. Therefore, TCP-1 subunits identified in the present study may act as TAAs required for capable of activating tumor-specific immunity.

In secretomes of HSV-1-infected macrophages, endogenous danger signal proteins were demonstrated as up-regulated proteins. They included HSPs, annexins, S100-A proteins, galectins, and thioredoxin superfamily members \[[@B16-cancers-10-00028]\]. The HSP family comprises proteins that act as molecular chaperones and catalyze the folding of proteins. HSPs bind to potential antigens under necrotic conditions and deliver them to various antigen-presenting cells \[[@B32-cancers-10-00028]\]. We found 20 proteins that are known as DAMPs ([Table 3](#cancers-10-00028-t003){ref-type="table"}). High abundance DAMPs including heat shock cognate 71 kDa protein, HSP90-alpha, HSP 70 kDa protein 4, HSP60, annexin A1, and peroxiredoxin-2 increased by RH2 infection, but the fold change observed was less than 1.4 fold. The levels of HSP90-beta, actin cytoplasmic 1, and galectin-3 were significantly higher in Med24 than in MedC. ATP is a known DAMP released extensively during ICD \[[@B4-cancers-10-00028]\]. We also confirmed that ATP-citrate synthase and ATP synthase were up-regulated proteins as DAMPs-related proteins. The spatiotemporally coordinated emission of specific DAMPs promotes the recruitment of antigen presenting cells to sites of ongoing ICD, their ability to take up dead cell-derived particulate materials, as well as their capacity to prime an adaptive immune response \[[@B33-cancers-10-00028]\]. Up-regulated DAMPs and DAMPs-related proteins observed in the present study were considered to be involved in the augmentation of antitumor immunity, operating as adjuvants.

Exosomes are small membrane-derived vesicles secreted by many types of normal and tumor cells \[[@B34-cancers-10-00028]\]. Xiang et al. \[[@B35-cancers-10-00028]\] reported the presence of DAMPs, such as HSPs, annexins, and histones, in exosomes, indicating the role of microvesicles as a form of excretion. DAMPs observed in the secretomes of MedC may be partly contained in exosomes. However, since oncolytic viruses including RH2 have been shown to induce apoptosis, necroptosis, autophagy, and pyroptosis \[[@B3-cancers-10-00028],[@B5-cancers-10-00028],[@B36-cancers-10-00028],[@B37-cancers-10-00028],[@B38-cancers-10-00028]\], increases in the secretion of DAMPs may be mostly due to the disintegration of the cell membrane by virus-mediated cell death.

Another result of the present study is the marked decrease in the release of proteins constituting the tumor microenvironment (TME). In the present study, 50 proteins were selected as down-regulated proteins that were reduced to less than 0.5 ([Table 2](#cancers-10-00028-t002){ref-type="table"}). They included fibronectin, thrombospondin-1, basement membrane-specific heparan sulfate proteoglycan core protein, fibrillin-1, 72 kDa type IV collagenase, procollagen C, and extracellular matrix protein 1. Since tumor and tumor stroma create the TME, which efficiently promotes tumor progression and supports evasion from antitumor immunity \[[@B39-cancers-10-00028],[@B40-cancers-10-00028]\], oncolytic HSV-1 may exert its antitumor effects by decreasing the release of ECM components.

Using the secretomes of HSV-1-infected macrophages, 5 envelope proteins, 3 tegument proteins, alkaline nuclease, and deoxyuridine 5′-triphosphate nucleotidohydrolase were identified \[[@B16-cancers-10-00028]\]. In the present study, viral structural components, i.e., the tegument, nucleocapsid, and envelope, were also detected in the supernatants of HSV-1-infected SCCVII cells. Furthermore, viral enzymes responsible for viral replication such as ribonucleoside-diphosphate reductase, single-strand DNA-binding protein, DNA polymerase processivity subunit, deoxyuridine triphosphatase, and thymidine kinase were identified. This result indicated that these cytoplasmic and nuclear viral proteins were passively released from dying cells. These proteins have been suggested to act as PAMPs, which promote inflammatory reactions and induce the infiltration of innate and adaptive immune cells.

Immunological abnormalities associated with TME inhibit the priming of antitumor adaptive immunity or tolerize tumor-specific CD4^+^ and CD8^+^ T cells \[[@B40-cancers-10-00028],[@B41-cancers-10-00028]\] ([Figure 1](#cancers-10-00028-f001){ref-type="fig"}A). Oncolytic virotherapy is supposed to release DAMPs, PAMPs, and TAA triggering proinflammatory cytokine release, DC maturation, and cytotoxic CD8^+^ T cell proliferation, and overcome TME-associated immunosuppression by reducing secretion of stromal components \[[@B5-cancers-10-00028],[@B40-cancers-10-00028],[@B42-cancers-10-00028],[@B43-cancers-10-00028]\] ([Figure 1](#cancers-10-00028-f001){ref-type="fig"}B). Using the supernatants of RH2-infected SCC cells, we herein demonstrated that DAMPs increased, and ECM proteins decreased. Viral gene products were also included. This may promote the immunological effects of the oncolytic HSV-1 on SCC cells. As a next step, it is important to confirm the role of each secreted protein in the antitumor effects of oncolytic HSV-1 by specific deletion.

4. Materials and Methods {#sec4-cancers-10-00028}
========================

4.1. Cells and Virus {#sec4dot1-cancers-10-00028}
--------------------

SCCVII cells derived from the cutaneous SCC of C3H mice were cultured with Eagle's minimal essential medium supplemented with 10% calf serum at 37 °C in a humidified atmosphere with 5% CO~2~ \[[@B13-cancers-10-00028],[@B14-cancers-10-00028]\]. HSV-1 RH2 lacking the γ34.5 gene and with multiple mutations including glycoprotein B were grown in Vero cell monolayers and infectivity was assessed using a plaque assay on a Vero cell monolayer \[[@B14-cancers-10-00028],[@B44-cancers-10-00028]\].

4.2. Preparation of Concentrated Supernatants of RH2-Infected Cells {#sec4dot2-cancers-10-00028}
-------------------------------------------------------------------

SCCVII cells were infected with RH2 at a multiplicity of infection of 10. After being incubated for 60 min for virus adsorption, cell monolayers were washed twice with phosphate-buffered saline, covered with serum-free medium, and cultured for 24 h. Culture supernatants were then harvested, and centrifuged at 1500 rpm for 10 min to remove cell debris. The supernatants were concentrated 30 times using Amicon^®^Ultra-15 3 K Centrifugal Filter Devices (Merck, Darmstadt, Germany) \[[@B13-cancers-10-00028]\]. Concentrates were exposed to ultraviolet irradiation at an intensity of 0.15 mW/cm^2^ for 30 min in order to inactivate the infectivity of the virus, filtered through a 0.20-µm filter, and named Med24. Mock-infected cells were also incubated in serum-free medium, supernatants were harvested 24 h later, treated as described for RH2-infected cells, and named MedC.

4.3. Proteomic Analysis {#sec4dot3-cancers-10-00028}
-----------------------

Three samples were used each in the proteomic analysis of Med24 and MedC \[[@B45-cancers-10-00028]\]. Protein concentrations in Med24 and MedC were assessed, and 4 volumes of cold acetone per 100 µg were added to each sample. They were kept at −20 °C overnight, and centrifuged at 15,000 rpm for 10 min to collect precipitates. Proteins were dried, and denatured by resuspending in 20 µL of lysis buffer (50 mM Tris-HCl, pH 9.0, 6 M uric acid, and 5% sodium deoxycholate), and reduced with 2 µL of reduction buffer (10 mM dithiothreitol) at 37 °C for 1 h. In order to block cysteine, 1 µL of cysteine-blocking buffer (55 mM iodoacetamide) was added, and proteins were alkylated in the dark at 25 °C for 30 min. After a 10-fold dilution of samples with 50 mM Tris-HCl (pH 9.0), proteins were disintegrated with trypsin at 37 °C for 16 h. An equal volume of ethyl acetate was added and acidified to a final concentration of 0.5% trifluoroacetic acid. The aqueous solution after centrifugation at 14,000 rpm for 2 min was harvested. Samples were desalted on C18-Stage Tips and labeled with the iTRAQ tag dissolved in 70 µL ethanol at room temperature for 1 h.

In the LC-MS/MS analysis, the Ultimate 3000 Nano LC system (Thermo Fisher Scientific, Waltham, MA, USA) was used for ultra performance liquid chromatography (UPLC) and connected to the Q-Exactive hybrid quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific) with a nano-electrospray ionization source. Labeled samples were injected into UPLC and concentrated in a C18 reverse phase trap column (100 µm I.D. × 5 mm length, Thermo Fisher Scientific) at a flow rate of 4 µL/min. Samples were then separated using a C18 reversed phase column (75 μm I.D. × 150 mm long, Nikkiso Tecnos, Tokyo) at a flow rate of 300 nL/min. A fixed mobile phase condition to Solvent A was water containing 0.1% formic acid and to Solvent B was acetonitrile containing 0.1% formic acid. Peptides were ionized by the positive mode of nano-electrospray ionization, which was a 1.8-kV capillary voltage.

Protein data were analyzed using Mascot Distiller v2.4 (Matrix Science, London, UK) <http://www.matrixscience.com/mascot_support_v2_4.html>, and a list of peaks was generated based on the recorded fragmentation spectra. In the identification of this protein, the UniProt amino acid sequence database (released on 4 March 2015: <http://www.uniprot.org/>) with biological species limited to the mouse (NCBI Taxonomy ID: 10090) and herpesviridae (ID: 10292) was used. The identified proteins were checked using the UniProt-GOA database (v140, <http://www.ebi.ac.uk/GOA>), and the annotation of Gene Ontology was added. Qualitative data and quantitative values were assessed using Mascot v2.4. In protein identification, the criteria of false rates of detection were less than 1%. The mass error was 10 ppm in Precursor Mass, and 0.01 Da in Fragment Mass. Due to the semi-quantitative nature of this approach, proteins were classified into three categories based on the values of iTRAQ quantitation (\<5, low abundance; 5 to 10, medium abundance; and \>10, high abundance) \[[@B46-cancers-10-00028]\].

4.4. Statistical Analysis {#sec4dot4-cancers-10-00028}
-------------------------

Statistical analyses were performed using the Student's *t*-test with Microsoft Excel (Microsoft, Redmond, WA, USA). Results were expressed as the mean ± SD. Differences were considered to be significant at *p* \< 0.05.

5. Conclusions {#sec5-cancers-10-00028}
==============

Our results indicate that a HSV-1 RH2 infection increases the release of danger signal proteins and viral gene products, but decreases the release of ECM components. These changes may alter the tumor microenvironment and promote anti-tumor immunity against SCC.
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![A model of the augmentation of antitumor immunity by an oncolytic virus. (**A**) Immunological abnormalities associated with TME inhibit the priming of antitumor adaptive immunity or tolerize tumor-specific CD4^+^ and CD8^+^ T cells; (**B**) Oncolytic viruses induce ICD with the release of secretomes containing DAMPs, PAMPs, proinflammatory cytokines, and TAA. This triggers DC maturation and cytotoxic CD8^+^ T cell proliferation. The reduced secretion of stromal components due to viral infection also overcomes TME-associated immunosuppression. TME, tumor microenvironment; ECM, extracellular matrix; TAA, tumor-associated antigen; ICD, immunogenic cell death; DC, dendritic cell; PAMPs, pathogen-associated molecular patterns; DAMPs, damage-associated molecular patterns.](cancers-10-00028-g001){#cancers-10-00028-f001}

cancers-10-00028-t001_Table 1

###### 

Up-regulated proteins in the abundance group of secretomes ^a^. ^a^ Proteins up-regulated by more than 1.4 fold by the strain RH2 infection are listed. ^b^ Mean of three assessments. \* *p* \< 0.05.

  Accession No.   Protein Name                                  MW (kDa)   iTRAQ Quantitation ^b^   Fold Change   *p*-Value   
  --------------- --------------------------------------------- ---------- ------------------------ ------------- ----------- ------------
  Q9QXS1          Plectin                                       534        79.7                     54            1.48        0.057
  B7FAU9          Filamin, alpha                                280        73.7                     49.7          1.48        0.004 \*
  P68372          Tubulin beta-4B                               50         54.7                     37            1.48        0.0027 \*
  Q9JKF1          Ras GTPase-activating-like protein IQGAP1     189        47.7                     33.7          1.42        0.09
  Q02053          Ubiquitin-like modifier-activating enzyme 1   118        40                       28            1.43        0.058
  Q5SXR6          Clathrin heavy chain                          192        40                       26.3          1.51        0.023 \*
  P80314          T-complex protein 1 subunit beta              57         39                       23.7          1.65        0.012 \*
  P63038          60-kDa heat shock protein, mitochondrial      61         32.4                     20.3          1.59        0.22
  P42932          T- complex protein 1 subunit theta            60         31.3                     20.3          1.54        0.0013 \*
  Q9CWJ9          Bifunctional purine biosynthesis              64         27.7                     17            1.63        0.021 \*
                  protein PURH                                                                                                
  P11983          T-complex protein 1 subunit alpha             60         25.7                     16.7          1.54        0.0088 \*
  P56480          ATP synthase subunit beta, mitochondrial      56         24                       17            1.41        0.42
  Q64737          Trifunctional purine biosynthetic protein     108        22.7                     16            1.42        0.12
                  adenosine-3                                                                                                 
  Q9JHU4          Cytoplasmic dynein 1 heavy chain 1            532        26.7                     12            2.22        0.16
  D3YW87          Filamin-C                                     289        33.3                     20.7          1.61        0.033 \*
  P80318          T-complex protein 1 subunit gamma             61         22.7                     13.3          1.7         0.0078 \*
  P80315          T-complex protein 1 subunit delta             58         19.3                     13.3          1.45        0.016 \*
  Q7TPV4          Myb-binding protein 1A                        152        21.3                     11.3          1.56        0.064
  Q8CGC7          Bifunctional glutamate/proline-tRNA ligase    170        19.7                     11.3          1.74        0.033 \*
  Q03265          ATP synthase subunit alpha, mitochondrial     60         19.3                     10.3          1.87        0.17
  P23116          Eukaryotic translation initiation factor 3    162        17                       11.3          1.5         0.078
                  subunit A                                                                                                   
  Q78PY7          Staphylococcal nuclease domain-containing     102        16.7                     11            1.51        0.12
                  protein1                                                                                                    
  B1AX58          Plastin-3                                     72         16                       11.3          1.41        0.00015 \*
  Q9D8N0          Elongation factor 1-gamma                     50         16.7                     10.3          1.61        0.18
  Q8BGQ7          Alanine\--tRNA ligase, cytoplasmic            107        15.7                     10.3          1.51        0.21
  Q61553          Fascin                                        55         15                       10.3          1.45        0.049 \*
  Q8CIE6          Coatomer subunit alpha                        138        14.7                     10            1.47        0.025 \*
  P21550          Beta-enolase                                  47         38                       25.3          1.5         0.002 \*
  Q922F4          Tubulin beta-6 chain                          50         27.7                     17.7          1.57        0.011 \*

cancers-10-00028-t002_Table 2

###### 

Down-regulate proteins in the abundance group of secretomes ^a^. ^a^ Proteins down-regulated by less than 0.5 fold by the RH2 infection are listed. ^b^ Mean of three assessments.

  Accession No.   Protein Name                                                    MW (kDa)   iTRAQ Quantitation ^b^   Fold Change   *p*-Value   
  --------------- --------------------------------------------------------------- ---------- ------------------------ ------------- ----------- ------------
  A0A087WR50      Fibronectin                                                     263        33.7                     99.0          0.34        0.00032
  P35441          Thrombospondin-1                                                130        15.7                     48.3          0.32        0.00045
  E9PZ16          Basement membrane-specific heparan                              470        9.3                      50.0          0.19        0.0011
                  sulfate proteoglycan core protein                                                                                             
  P97298          Pigment epithelium-derived factor                               46         16.7                     42.7          0.39        0.0011
  A2AQ53          Fibrillin-1                                                     312        10.0                     41.7          0.24        0.0000830
  Q3UQ28          Peroxidasin homolog                                             165        6.7                      36.3          0.18        0.0019
  P33434          72-kDa type IV collagenase                                      74         11.0                     31.3          0.35        0.0074
  E9PZ00          Prosaposin                                                      61         9.0                      28.3          0.32        0.0016
  D3Z598          Latent-transforming growth factor beta-binding protein 4        167        6.0                      29.7          0.2         0.00022
  Q07797          Galectin-3-binding protein                                      64         7.3                      25.7          0.29        0.00022
  P28653          Biglycan                                                        42         4.7                      27.7          0.17        0.0011
  P10605          Cathepsin B                                                     37         10.0                     21.3          0.47        0.023
  Q00493          Carboxypeptidase E                                              53         10.3                     21.0          0.49        0.011
  Q8VHY0          Chondroitin sulfate proteoglycan 4                              252        6.3                      25.0          0.25        0.0015
  Q06890          Clusterin                                                       52         6.3                      23.3          0.27        0.00044
  Q9R118          Serine protease HTRA1                                           51         7.0                      22.3          0.31        0.00078
  P07214          SPARC                                                           34         6.3                      22.7          0.28        0.00029
  Q61398          Procollagen C                                                   50         4.7                      24.3          0.19        0.0000940
  Q9QZF2          Glypican-1                                                      61         7.3                      19.7          0.37        0.0078
  Q640N1          Adipocyte enhancer-binding protein 1                            128        5.7                      20.7          0.27        0.0004
  Q8BND5          Sulfhydryl oxidase 1                                            83         5.3                      21.0          0.25        0.0018
  Q02819          Nucleobindin-1                                                  53         7.7                      17.3          0.44        0.016
  Q9R0E2          Procollagen-lysine, 2-oxoglutarate                              84         5.7                      17.7          0.32        0.0037
                  5-dioxygenase 1                                                                                                               
  Q61468          Mesothelin                                                      69         6.3                      16.7          0.38        0.00039
  M0QWP1          Agrin                                                           217        2.7                      18.3          0.15        0.00000480
  Q61508          Extracellular matrix protein 1                                  63         3.0                      17.7          0.17        0.0014
  O08665          Semaphorin-3A                                                   89         5.3                      15.0          0.36        0.0054
  Q9WVH9          Fibulin-5                                                       50         2.3                      18.0          0.13        0.00071
  Q60963          Platelet-activating factor acetylhydrolase                      49         2.3                      17.7          0.13        0.00037
  O88325          Alpha-N-acetylglucosaminidase                                   83         3.0                      15.7          0.19        0.00046
  P21460          Cystatin-C                                                      16         5.3                      13.3          0.34        0.0058
  P55065          Phospholipid transfer protein                                   54         0.7                      18.0          0.04        0.00048
  P25785          Metalloproteinase inhibitor 2                                   24         5.7                      12.7          0.45        0.012
  Q8QZR4          Out at first protein homolog                                    32         4.7                      13.7          0.34        0.0049
  G3XA35          MCG116562, isoform CRA_a                                        263        4.7                      13.3          0.35        0.007
  Q8CE08          Prostatic acid phosphatase                                      44         2.7                      15.3          0.17        0.0000700
  P41245          Matrixmetalloproteinase -9                                      81         3.0                      14.7          0.2         0.0013
  P12023          Amyloid beta A4 protein                                         87         3.3                      13.3          0.25        0.0042
  P18242          Cathepsin D                                                     45         5.0                      11.7          0.43        0.034
  Q9WV54          Acid ceramidase                                                 45         2.7                      14.0          0.19        0.00071
  P08121          Collagen alpha-I (III) chain                                    139        2.0                      13.3          0.15        0.011
  G3UWC2          N-acetylated alpha-linked acidic dipeptidase 2, isoform CRA_a   87         1.7                      11.7          0.14        0.0013
  Q62165          Dystroglycan                                                    97         2.3                      10.3          0.23        0.00043
  Q62356          Follistatin-related protein 1                                   35         2.3                      10.0          0.23        0.0019
  P11087          Collagen alpha-1(I) chain                                       138        2.0                      10.3          0.19        0.011
  Q9EPL2          Calsyntenin-1                                                   109        0.7                      11.3          0.06        0.0015
  O88207          Collagen alpha-1(V) chain                                       184        0                        12.0          0           0.00048
  Q04857          Collagen alpha-1 (VI) chain                                     108        0                        12.0          0           0.0000310
  O09159          Lysosomal alpha-mannosidase                                     115        0                        10.0          0           0.0000652
  P47880          Insulin-like growth factor-biding protein 6                     25         0                        10.0          0           0.00098
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###### 

DAMPs and DAMPs-related proteins in secretomes. ^a^ Mean of three assessments. \* *p* \< 0.05.

  Accession No.            Protein Name                                MW (kDa)   iTRAQ Quantitation ^a^   Fold Change   *p*-Value   
  ------------------------ ------------------------------------------- ---------- ------------------------ ------------- ----------- -----------
  DAMPs                                                                                                                              
  P63017                   Heat shock cognate 71-kDa protein           71         68.0                     63.7          1.07        0.41
  P11499                   Heat shock protein HSP 90-beta              83         66.7                     56.7          1.18        0.046 \*
  P60710                   Actin, cytoplasmic 1                        42         49.0                     36.0          1.36        0.027 \*
  Q3U2G2                   Heat shock 70 kDa protein 4                 94         36.0                     30.7          1.17        0.071
  P07901                   Heat shock protein HSP 90-alpha             85         57.7                     49.7          1.16        0.052
  P10107                   Annexin A1                                  39         30.0                     29.0          1.03        0.75
  P10853                   Histone H2B type 1-F/J/L                    14         27.3                     29.3          0.93        0.71
  P63038                   60-kDa heat shock protein, mitochondrial    61         32.3                     20.3          1.59        0.22
  P16045                   Galectin-1                                  15         22.3                     19 .0         1.18        0.067
  P07356                   Annexin A2                                  39         15.3                     14.3          1.07        0.72
  Q61171                   Peroxiredoxin -2                            22         15.0                     13.7          1.10        0.33
  O08709                   Peroxiredoxin -6                            25         11.7                     9.7           1.21        0.18
  Q9JMH6                   Thioredoxin reductase 1, cytoplasmic        67         10.7                     8.3           1.28        0.28
  Q61699                   Heat shock protein 105 kDa                  96         12.3                     8.0           1.54        0.25
  P16110                   Galectin-3                                  28         10.0                     5.7           1.67        0.031 \*
  P99029                   Peroxiredoxin-5, mitochondrial              22         9.0                      6.3           1.42        0.091
  P63158                   High mobility group protein B1              25         5.7                      4.7           1.22        0.66
  P15864                   Histone H1.2                                21         3.0                      7.0           0.43        0.0081 \*
  P10639                   Thioredoxin                                 12         5.7                      3.7           1.55        0.10
  P14211                   Calreticulin                                48         3.7                      3.3           1.12        0.90
  DAMPs-related proteins                                                                                                             
  Q3V117                   ATP-citrate synthase                        121        28.0                     21.0          1.33        0.025 \*
  P56480                   ATP synthase subunit beta, mitochondrial    56         24.0                     17.0          1.41        0.42
  Q03265                   ATP synthase subunit alpha, mitochondrial   60         19.3                     10.3          1.87        0.17
  Q9DB20                   ATP synthase subunit O, mitochondrial       23         4.7                      4.0           1.17        0.80
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###### 

HSV-1 proteins in secretomes. ^a^ Mean of three assessments. UL, unique sequence of the L component; US, unique sequence of the S component; ICP, infected cell protein; VP, virion polypeptide.

  Accession No.   Protein Name                                               MW (kDa)   Gene   iTRAQ Quantitation ^a^
  --------------- ---------------------------------------------------------- ---------- ------ ------------------------
  F8RG70          Ribonucleoside-diphosphate reductase large subunit, ICP6   124        UL39   33.7
  D3YP93          Single-stranded DNA-binding protein, ICP8                  128        UL29   32.7
  L0N5H2          DNA polymerase processivity subunit                        51         UL42   19.3
  B9VQC5          Transcriptional regulator ICP4                             133        α4     7.7
  D3YP82          Major capsid protein, VP5                                  149        UL19   14.3
  A0A0B5E4C5      UL12, Exonuclease                                          67         UL12   13.0
  D3YPB9          Multifunctional expression regulator, ICP27                55         UL54   13.0
  A0A0F7GRC1      Deoxyuridine triphosphatase                                39         UL50   10.0
  F8RCG6          Tegument protein UL37                                      121        UL37   10.0
  A0A0B5E4D5      Thymidine kinase                                           41         UL23   8.3
  A0A0B5E4F4      VP13/VP14                                                  74         UL47   7.7
  D0V7M2          Capsid protein VP23                                        34         UL18   7.7
  A2I996          Glycoprotein D                                             43         US6    6.7
  L0N6C7          Envelope glycoprotein E                                    59         US8    5.3
  P10224          Ribonucleoside-diphosphate reductase small subunit         38         UL40   6.0
  F8RCR4          Tegument protein VP11/12                                   78         UL46   5.3
  F8RDC2          DNA packaging tegument protein UL25                        63         UL25   5.0
  L0N3F0          Tegument protein VP22                                      32         UL49   4.3
  D3YPB2          Transactivating tegument protein VP16                      54         UL48   3.7
  A0A0F7CY40      Nuclear egress membrane protein                            30         UL34   4.7
  A0A0F7GTB2      Capsid maturation protease                                 67         UL26   1.7
  A0A089YQM2      Glycoprotein B                                             100        UL27   1.7
  A0A089YQK4      UL2, Uracil-DNA glycosylase                                36         UL2    1.3
  F8RFA5          Tegument protein UL21                                      58         UL21   1.3
  A0A0B5EE83      Glycoprotein I                                             41         US7    1.0
  D3YP85          Envelope glycoprotein H                                    90         UL22   0.7
  L0N3E3          Envelope glycoprotein C                                    55         UL44   0.7
  L0N6J6          DNA polymerase                                             137        UL30   0.7
  A0A089WZ14      Type II membrane protein                                   18         UL45   0.7
